Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction

Journal of Immunotherapy

Volumn 30, Issue 7, 2007, Pages 684-693

  Turatti, Fabio ^a   Figini, Mariangela ^a   Balladore, Emanuela ^a   Alberti, Paola ^a   Casalini, Patrizia ^a   Marks, James D ^b   Canevari, Silvana ^a   Mezzanzanica, Delia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chimeric immune receptor; Cytotoxicity; Human T cells

Indexed keywords

ANTIBIOTIC G 418; CD3 ANTIGEN; CHIMERIC IMMUNE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; LYMPHOCYTE RECEPTOR; SILVER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL INTERACTION; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; GENETIC TRANSDUCTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; HUMAN CELL; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR AFFINITY; TUMOR CELL;

ANTIBODY AFFINITY; ANTIGENS, NEOPLASM; CELL LINE; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKOCYTES, MONONUCLEAR; RECEPTOR, ERBB-2; RECEPTORS, IMMUNOLOGIC; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 34748881184     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3180de5d90     Document Type: Article

References (40)

1. Mapara MY, Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol. 2004;22:1136-1151.
2. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004;5:292-302.
3. Sanz L, Blanco B, Alvarez-Vallina L. Antibodies and gene therapy: teaching old 'magic bullets' new tricks. Trends Immunol. 2004;25:85-91.
4. Cao Y, Lam L. Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev. 2003;55:171-197.
5. Mansoor W, Gilham DE, Thistlethwaite FC, et al. Engineering T cells for cancer therapy. Br J Cancer. 2005;93:1085-1091.
6. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106-6115.
7. Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA. 1989;86:10024-10028.
8. Eshhar Z, Gross G, Waks T, et al. T-bodies: chimeric receptors with antibody-type specificity. Methods Enzymol. 1995;8:133-142.
9. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res. 1995;55:3369-3373.
10. Willemsen RA, Debets R, Chames P, et al. Genetic engineering of T cell specificity for immunotherapy of cancer. Hum Immunol. 2003;64:56-68.
11. Alvarez-Vallina L. Genetic approaches for antigen-selective cell therapy. Curr Gene Ther. 2001;1:385-397.
12. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol. 2002;2:227-238.
13. McCall AM, Shahied L, Amoroso AR, et al. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol. 2001;166:6112-6117.
14. Bortoletto N, Scotet E, Myamoto Y, et al. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur J Immunol. 2002;32:3102-3107.
15. Chames P, Willemsen RA, Rojas G, et al. TCR-like human antibodies expressed on human CTLs mediate antibody affinity-dependent cytolytic activity. J Immunol. 2002;169:1110-1118.
16. Schier R, Marks JD, Wolf EJ, et al. In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library. Immunotechnology. 1995;1:73-81.
17. Schier R, McCall A, Adams GP, et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J Mol Biol. 1996;263:551-567.
18. Chmielewski M, Hombach A, Heuser C, et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. J Immunol. 2004;173:7647-7653.
19. Turatti F, Figini M, Alberti P, et al. Highly efficient redirected antitumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med. 2005;7:158-170.
20. Fogh J, Bean MA, Bruggen J. Comparison of a human tumor cell line before and after growth in the nude mouse. In: Fogh J, Giovanella B, eds. The Nude Mouse in Experimental and Clinical Research. New York: Academic Press; 1978:215-234.
21. Casalini P, Botta L, Menard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem. 2001;276:12449-12453.
22. Centis F, Tagliabue E, Uppugunduri S, et al. p185 HER2/neu epitope mapping with murine monoclonal antibodies. Hybridoma. 1992;11:267-276.
23. Tzahar E, Pinkas-Kramarski R, Moyer JD, et al. Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J. 1997;16:4938-4950.
24. Weijtens ME, Willemsen RA, Hart EH, et al. A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. 1998;5:1195-1203.
25. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA. 1993;90:720-724.
26. Mazzoni A, Mezzanzanica D, Jung G, et al. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma. Cancer Res. 1996;56:5443-5449.
27. Mezzanzanica D, Canevari S, Mazzoni A, et al. Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anti-carbohydrate specificity on T cells. Cancer Gene Ther. 1998;5:401-407.
28. Hombach A, Schneider C, Sent D, et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer. 2000;88:115-120.
29. Gilham DE, O'Neil A, Hughes C, et al. Primary polyclonal human T lymphocytes targeted to carcino-embryonic antigens and neural cell adhesion molecule tumor antigens by CD3zeta-based chimeric immune receptors. J Immunother. 2002;25:139-151.
30. Qian JH, Titus JA, Andrew SM, et al. Human peripheral blood lymphocytes targeted with bispecific antibodies release cytokines that are essential for inhibiting tumor growth. J Immunol. 1991;146:3250-3256.
31. Valitutti S, ller S, Cella M, et al. Serial triggering of many T-cell receptors by a few peptide-MHC complexes. Nature. 1995;375:148-151.
32. Matsui K, Boniface JJ, Reay PA, et al. Low affinity interaction of peptide-MHC complexes with T cell receptors. Science. 1991;254:1788-1791.
33. Borovsky Z, Mishan-Eisenberg G, Yaniv E, et al. Serial triggering of T cell receptors results in incremental accumulation of signaling intermediates. J Biol Chem. 2002;277:21529-21536.
34. Valitutti S, Dessing M, Aktories K. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J Exp Med. 1995;181:577-584.
35. Gray LS, Gnarra JR, Sullivan JA, et al. Spatial and temporal characteristics of the increase in intracellular Ca2+ induced in cytotoxic T lymphocytes by cellular antigen. J Immunol. 1988;141:2424-2430.
36. Valitutti S, Lanzavecchia A. Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition. Immunol Today. 1997;18:299-304.
37. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity. 1998;8:89-95.
38. Valitutti S, Muller S, Dessing M, et al. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J Exp Med. 1996;183:1917-1921.
39. Langenkamp A, Casorati G, Garavaglia C, et al. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification. Eur J Immunol. 2002;32:2046-2054.
40. Pupa SM, Menard S, Morelli D, et al. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene. 1993;8:2917-2923.